INTRODUCTION
African children with severe Plasmodium falciparum malaria often present with metabolic complications which include impairment of glucose homeostasis, cardiovascular and kidney functions partly ascribed to P. falciparum infection and/or drugs used manage malaria [1] .
The traditional oral chloroquine (CHQ) dosin¬g schedule of 4 tablets, equivalent to 600 mg active base, on day 1, followed by 2 tablets, equivalent to 300 mg active base, 6 hours later, and 2 tablets, 300 mg, a day for the next 2 days, giving a total of 1200 mg contributes to high plasma CHQ concentrations.
Alternative methods of CHQ delivery have, therefore, been suggested, in an effort to modify the dosing schedule which may improve patient comfort and compliance.
Against this background, literature evidence indicates that transdermal drug delivery provides sustained controlled release of drugs directly into the systemic circulation [2] .
OBJECTIVES
• To develop a novel CHQ-formulation that delivers sustained slow CHQ into the systemic circulation.
• To investigate the ability of this CHQ formulation to clear the malaria parasites in Plasmodium berghei-infected male Sprague-Dawley rats.
• Evaluate the effects of the transdermal delivery of CHQ on renal function and on blood glucose homeostasis in malaria infected rats.
MATERIALS AND METHODS

Patch preparation
Pectin was dissolved in deionized water followed by adding CHQ, DMSO and antioxidants. After freezing, CaCl 2 was added for cross-linking and patch formation. The patches were then stored in the refrigerator at 2 o C until use.
Determination of the amount of CHQ in patches
The amount of CHQ in the CHQ pectin patch was determined spectrophotometrically after dissolving the patch of known areas in de-ionized water. The blank contained CHQ free pectin patches in de-ionized water.
Malaria induction
Malaria was induced in male Sprague-Dawley rats (90-190 g body weight) with a single intraperitoneal injection of P. berghei (105 parasitised red blood cells).
Experimental design
Male Sprague-Dawley rats were divided into non-infected (control) and P. berghei infected groups (n=6 in each group). The groups were further subdivided into those treated orally with CHQ diphosphate powder or transdermally applied Pectin CHQ patch formulations for assessment of the effects on parasitaemia, blood glucose and renal functions. 
Sub-chronic effects of CHQ
Terminal studies
To assess the effects of oral and transdermal CHQ treatments on some biochemical parameters, plasma CHQ profiles, electrolytes, AVP and insulin concentrations, separate groups of non-infected and P. berghei infected animals (n=6) were sacrificed on the last day treatment and post-treatment period.
Statistical analysis
All data presented as means ±SEM. Graph Pad Instat software (version 5) using one way analysis of variance (ANOVA) followed by Tukey-Kramer multiple comparison test was used. P values < 0.05 were considered significant.
RESULTS
Chloroquine loading efficiency
The amidated CHQ pectin patches contained 15.9 mg/ml translating into a dose of 53 mg/kg for a 300 g rat. The percentage CHQ incorporation into the matrix patch was 74%. 
Effects of CHQ treatments Parasitaemia
Plasma AVP and biochemical parameters
The plasma K + concentrations of animals treated twice daily with oral CHQ were significantly elevated when compared with pectin CHQ matrix patch treated animals ( Table 2) . Oral CHQ treatment significantly (p < 0.05) increased plasma AVP by comparison to topical applied pectin-CHQ matrix patch. The current study has demonstrated the sustained controlled release of CHQ from the pectin matrix patch, demonstrating the therapeutic ability to clear P. berghei malaria parasites from systemic circulation. The once off application of the CHQ patch was able to circumvent the adverse effects of oral CHQ delivery on blood glucose homeostasis and renal function. We conclude that the pectin-CHQ matrix patch has the potential avert the adverse effects that are associated with oral administration of CHQ.
